Silence Therapeutics (NASDAQ:SLN) Given Outperform Rating at William Blair

William Blair reissued their outperform rating on shares of Silence Therapeutics (NASDAQ:SLN - Free Report) in a research note released on Tuesday morning,RTT News reports.

A number of other research firms also recently weighed in on SLN. Chardan Capital reaffirmed a "buy" rating and set a $55.00 price target on shares of Silence Therapeutics in a research note on Thursday, November 14th. Jefferies Financial Group assumed coverage on shares of Silence Therapeutics in a research note on Tuesday, September 3rd. They issued a "buy" rating and a $40.00 target price on the stock. HC Wainwright reaffirmed a "buy" rating and set a $75.00 price target on shares of Silence Therapeutics in a report on Friday. Finally, Morgan Stanley reaffirmed an "overweight" rating and set a $49.00 price target on shares of Silence Therapeutics in a report on Tuesday, October 8th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, Silence Therapeutics has a consensus rating of "Buy" and an average target price of $57.20.

Silence Therapeutics Trading Down 36.8 %

Shares of SLN stock traded down $4.05 during trading hours on Tuesday, hitting $6.97. The company's stock had a trading volume of 4,518,771 shares, compared to its average volume of 224,298. The business has a fifty day moving average of $17.58 and a 200-day moving average of $18.94. The stock has a market cap of $208.60 million, a price-to-earnings ratio of -4.44 and a beta of 1.30. Silence Therapeutics has a twelve month low of $6.31 and a twelve month high of $27.72.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the business. Y Intercept Hong Kong Ltd boosted its holdings in shares of Silence Therapeutics by 22.9% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 21,078 shares of the company's stock valued at $383,000 after buying an additional 3,923 shares during the period. Point72 Asset Management L.P. boosted its stake in Silence Therapeutics by 219.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 467,800 shares of the company's stock valued at $8,505,000 after purchasing an additional 321,300 shares during the period. Parkman Healthcare Partners LLC boosted its stake in Silence Therapeutics by 71.8% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 497,870 shares of the company's stock valued at $9,051,000 after purchasing an additional 208,029 shares during the period. Ikarian Capital LLC grew its position in Silence Therapeutics by 15.9% in the 3rd quarter. Ikarian Capital LLC now owns 587,343 shares of the company's stock worth $10,678,000 after purchasing an additional 80,678 shares during the last quarter. Finally, Janus Henderson Group PLC increased its stake in shares of Silence Therapeutics by 32.8% in the third quarter. Janus Henderson Group PLC now owns 1,087,228 shares of the company's stock valued at $19,798,000 after purchasing an additional 268,250 shares during the period. 98.73% of the stock is owned by institutional investors and hedge funds.

Silence Therapeutics Company Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.